drugset / Trial / NCT01002820

A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601

NCT01002820

Phase 2 Completed 11 enrolled Marinus Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This study is designed to provide ganaxolone to those patients deriving significant benefit from current treatment in protocol 1042-0601.

Timeline

Start
2009-10
Primary completion
2010-10
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Ganaxolone Small molecule 500 mg
Subject Ganaxolone Small molecule 1500 mg